Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Vaccine. 2020 Nov 25;38(50):7897-7904. doi: 10.1016/j.vaccine.2020.10.071. Epub 2020 Nov 4.
Rubella virus (RV) was eliminated in the United States in 2004, although a small portion of the population fails to develop long-term immunity against RV even after two doses of the measles-mumps-rubella (MMR) vaccine. We hypothesized that inherent biological differences in cytokine and chemokine signaling likely govern an individual's response to a third dose of the vaccine.
Healthy young women (n = 97) were selected as study participants if they had either low or high extremes of RV-specific antibody titer after two previous doses of MMR vaccine. We measured cytokine and chemokine secretion from RV-stimulated PBMCs before and 28 days after they received a third dose of MMR vaccine and assessed correlations with humoral immune response outcomes.
High and low antibody vaccine responders exhibited a strong pro-inflammatory cellular response, with an underlying Th1-associated signature (IL-2, IFN-γ, MIP-1β, IP-10) and suppressed production of most Th2-associated cytokines (IL-4, IL-10, IL-13). IL-10 and IL-4 exhibited significant negative associations with neutralizing antibody titers and memory B cell ELISpot responses among low vaccine responders.
IL-4 and IL-10 signaling pathways may be potential targets for understanding and improving the immune response to rubella vaccination or for designing new vaccines that induce more durable immunity.
风疹病毒(RV)于 2004 年在美国被消灭,尽管即使在接种了两剂麻疹-腮腺炎-风疹(MMR)疫苗后,仍有一小部分人群未能对 RV 产生长期免疫力。我们假设细胞因子和趋化因子信号的固有生物学差异可能决定了个体对第三剂疫苗的反应。
如果健康的年轻女性(n=97)在前两剂 MMR 疫苗接种后 RV 特异性抗体滴度处于低或高极端值,则选择她们作为研究参与者。我们测量了 RV 刺激的 PBMCs 在接种第三剂 MMR 疫苗前后的细胞因子和趋化因子分泌情况,并评估了与体液免疫反应结果的相关性。
高和低抗体疫苗应答者表现出强烈的促炎细胞反应,具有潜在的 Th1 相关特征(IL-2、IFN-γ、MIP-1β、IP-10),并抑制了大多数 Th2 相关细胞因子(IL-4、IL-10、IL-13)的产生。低疫苗应答者的中和抗体滴度和记忆 B 细胞 ELISpot 反应与 IL-10 和 IL-4 呈显著负相关。
IL-4 和 IL-10 信号通路可能是理解和改善风疹疫苗免疫反应的潜在靶点,或设计诱导更持久免疫力的新型疫苗的靶点。